Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Yves Reginster

Showing results (1-10 of 455) with videos related to

Pageof 46
Sort By:
Expert Opinion on Pharmacotherapy|May 8, 2010
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96Jean-Yves Reginster
Expert Opinion on Pharmacotherapy|October 13, 2005
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosisJean-Yves Reginster
Revue Medicale De La Suisse Romande|April 21, 2004
[Chondromodulation in 2003: dream or reality?]Jean-Yves Reginster
Current Medical Research and Opinion|May 19, 2005
The high prevalence of inadequate serum vitamin D levels and implications for bone healthJean-Yves Reginster
Bone|January 31, 2006
Adherence and persistence: impact on outcomes and health care resourcesJean-Yves Reginster
Drugs|December 24, 2010
Antifracture efficacy of currently available therapies for postmenopausal osteoporosisJean-Yves Reginster
Expert Opinion on Drug Safety|July 15, 2014
Cardiac concerns associated with strontium ranelateJean-Yves Reginster
Expert Review of Clinical Pharmacology|January 6, 2012
Adverse drug reactions to osteoporosis treatmentsRené Rizzoli, Jean-Yves Reginster
Expert Opinion on Pharmacotherapy|November 6, 2010
Strontium ranelate: a look back at its use for osteoporosisJean-Yves Reginster, Audrey Neuprez
Best Practice & Research. Clinical Endocrinology & Metabolism|November 26, 2008
Bone-forming agents in the management of osteoporosisAudrey Neuprez, Jean-Yves Reginster
Pageof 46

Showing results (1-10 of 455) with videos related to

Sort By:
Pageof 46
Expert Opinion on Pharmacotherapy|May 8, 2010
Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96Jean-Yves Reginster
Expert Opinion on Pharmacotherapy|October 13, 2005
Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosisJean-Yves Reginster
Revue Medicale De La Suisse Romande|April 21, 2004
[Chondromodulation in 2003: dream or reality?]Jean-Yves Reginster
Current Medical Research and Opinion|May 19, 2005
The high prevalence of inadequate serum vitamin D levels and implications for bone healthJean-Yves Reginster
Bone|January 31, 2006
Adherence and persistence: impact on outcomes and health care resourcesJean-Yves Reginster
Drugs|December 24, 2010
Antifracture efficacy of currently available therapies for postmenopausal osteoporosisJean-Yves Reginster
Expert Opinion on Drug Safety|July 15, 2014
Cardiac concerns associated with strontium ranelateJean-Yves Reginster
Expert Review of Clinical Pharmacology|January 6, 2012
Adverse drug reactions to osteoporosis treatmentsRené Rizzoli, Jean-Yves Reginster
Expert Opinion on Pharmacotherapy|November 6, 2010
Strontium ranelate: a look back at its use for osteoporosisJean-Yves Reginster, Audrey Neuprez
Best Practice & Research. Clinical Endocrinology & Metabolism|November 26, 2008
Bone-forming agents in the management of osteoporosisAudrey Neuprez, Jean-Yves Reginster
Pageof 46